eu funding opportunities for health research in …...eu funding opportunities for health research...

EU funding opportunities for Health research in Horizon 2020 HIMSS IMPACT 18, Potsdam, October 18 2018

Dr. Uta Baddack-Werncke www.nks-lebenswissenschaften.de

HIMSS IMPACT 18, October 18 2018 2

• Introduction to the Health National Contact Points • How does Horizon 2020 work? • Funding Opportunities 2019 and beyond • Further funding opportunities • Rules for Participation – Short version


Akteure und Interaktionen

EU- Liaison Officers

EU- Commission

Researchers

Industry etc.

National Contact Point Health / Life Sciences


EU- Commission

Member States Research Institute/ Company

Local EU-officer

National Contact Points

Commissioned by the

Strategy for succesful participation in H2020


Does your idea fit into Horizon 2020

Scanning programmes and initiatives to find suitable funding possibilities

Individual consultancy: proposal planning / proposal preparation / project management

Critical review of proposal outlines/drafts and full proposals

Workshops “Proposal Writing”

Partnering activities / Partner Search

Guidelines and supporting documents

Workshops or Webinars: clinical trials / ethics / IPR, proposal sections…

Newsletter: alert service for calls, important european developments and events

Internet / Website: open calls and other relevant funding opportunities

Services of National Contact Points: free of charge


Horizon 2020 – a political programme

Competitiveness

Policy Support

Solve Societal

Challenges

Innovation

Coverage of the whole value chain in one programme


The 3 Pillars of Horizon 2020

I. Excellent Science

II. Industrial leadership

III. Societal

Challenges

• science-lead • mainly bottom-up knowledge base for the future

• Industry-lead • Development of key enabling

technologies • Definition of topics by industry • Support of SMEs Companies for the future

• Policy-lead (EU 2020) Research to solve societal challenges


Funding possibilites for ideas in Health Research

I. Excellent science

II. Industrial Leadership

III. Societal Challenges

LEIT Leadership in enabling

and Industrial Technologies

ICT Nanotechnologies

Advanced materials Biotechnology

Advanced manufacturing and processing

Space

Access to risk finance

Innovation in SMEs

European Research Council - ERC

Future & emerging Technologies - FET

Marie-Skłodowska-Curie

Research infrastructures

Joint Research

centre JRC

EIT

Health, demographic change and wellbeing

Food security, sustainable agriculture and forestry, water

research and bioeconomy

Secure, clean and efficient energy

Smart, green and integrated transport

Climate action, environment, ressource efficiency, raw materials

Europe in a changing world - inclusive, innovative and

reflective societies Secure Societies - freedom and

security of Europe and its citizens

Spreading excellence

and widening participation

Science with and for

society


Horizon 2020 – Strategic Programme and work programme


What are the Framework Programmes?

• „Framework Programmes of the European Community for research, technological development and demonstration activities“

• are the measure of the EU to support science and technology at the European level.

Aims (as specified in the EU-Treaty): • strengthening the scientific and technological bases of the EU • achieving a European research area

• researchers can move freely • scientific knowledge and technology circulate freely

• Enhancing competitiveness of the EU including its industries • Support for research needs of other policies (health, developmental,

agricultural…..)


Trends in Horizon 2020

• Stronger focus on innovation: not only development of new products and services but also non-technical and social innovation

• Focus on activities close to the end user and the market such as demonstrations, pilots, proof-of-concept

• Implementation through grants, prizes, procurement and financial instruments

• Bottom-up approaches and open, light and fast schemes possible in all parts of the programme

• Stronger synergies with public-public partnerships, national and regional programmes

• Combination of funding through Horizon 2020 and private funding in public-private partnerships (e.g. Joint Technology Initiatives)


Horizon 2020 budget


Excellent Science

Aims

• To strengthen and widen excellence of science • Consolidation of the European research area • Increase global competitiveness of EU research and innovation

systems

Trends

• Research-driven approaches • ‘Bottom-up’ • Science as the driver


Future & Emerging Technologies - FET

Marie-Skłodowska-Curie - MSC


Part I Excellent Science


European Research Council Bottom-up Starting Grants 2-7 years after PhD, ≤ € 2 mill. for max. 5 years Consolidator Grants 7-12 years after PhD, ≤ € 2.75 mill. for max. 5 years Advanced Grants for experienced excellent researchers, ≤ € 3.5 mill. for max. 5 years Synergy Grants 2-4 principal investigators, ≤ € 15 mill. for max. 6 years Proof-of-Concept bridge gap between research and early market activities € 0.15 mill. (for ERC grantees only)

www.nks-erc.de

Total budget: € 13.1 billion Part I

Excellent Science






Future and Emerging Technologies

Visionary research for novel technologies FET Open bottom-up, early phases of research individual collaborative projects FET Proactive targeted funding of new topics support for research clusters development of communities FET Flagship definition of research agenda large-scale research initiatives: GRAPHENE and Human Brain Project

www.eubuero.de/fet-netzwerk.htm


Excellent Science






Marie Skłodowska-Curie Actions: Mobility Bottom-up Innovative Training Networks (ITN) training of doctoral students Individual Fellowships (IF) funding of experienced researchers Research & Innovation Staff Exchange (RISE) exchange of personnel within collaborative projects COFUND co-fund mechanism for mobility programmes

www.nks-mobilitaet.de


Excellent Science






Research Infrastructures

Aims: • Networking between existing research

infrastructures • Establishment of new research institutes and

facilities of pan-European interest Funding instrument: Combination of collaborative project and coordination and support action

www.eubuero.de


Excellent Science



Marie-Skłodowska-Curie



Industrial Leadership

Aims • Boost the development of technologies and innovations • Key Enabling Technologies (KET)

• Build foundation for tomorrow’s companies

• Support to innovative European SMEs Trends • Strategic agendas of industry define the calls

• Close-to-market activities

• Joint Technology Initiatives (JTI)

• ‘Industry in the driver seat’

II. Industrial

Leadership






Space


Innovation in SMEs


Innovation in Small & medium enterprises (SME)

• Aim: close the gap for early phases of high risk research and innovation

• Broad meaning of innovation: technological and non-technological, social and service innovation (European added-value)

• Bottom-up approach

• Easy access through simple rules and procedures

• Implementation: different measures, e.g. SME instrument

II. Industrial

Leadership






Space


Innovation in SMEs


Societal Challenges

Aims • Support the political goals as defined in the Europe 2020

Strategy • Cover the whole cycle from research and innovation to

the market • Needs critical mass, interdisciplinarity

Trends • Coordination with nationally funded European activities

and global initiatives • Focus on 7 priority areas • Support for the whole innovation chain: research,

technological development, demonstration and innovation activities

III. Societal Challenges


Food security, sustainable agriculture and forestry, water

research and bioeconomy





reflective societies Secure Societies - freedom and

security of Europe and its citizens


Societal Challenge 1: Health, demographic change and wellbeing

Challenges • Increasing costs for health care systems

due to ageing population • Requires effective prevention, treatment

and management of disease and disability • Focus: chronic diseases,

infectious diseases (non exclusive) Aims • Improve life long health and wellbeing • High quality, sustainable health care systems • Improve growth and employment

III. Societal

Challenges


Food security, sustainable agriculture and forestry,

water research and bioeconomy





reflective societies Secure Societies - freedom and security of Europe and

its citizens


Societal Challenge 1: Health, demographic change and wellbeing

Approach • Support to activities covering the whole innovation chain

from basic research to market entry • Interdisciplinarity (cohorts, „-omics“, ICT (e-health),

Big Data, smart solutions, assistive devices, personalised medicine…)

• “Cross cutting issues” addressed whenever necessary, e.g. social sciences, economics and humanities, gender, international cooperation

• Complementarity and synergies with JPIs, EIP, PPPs • International cooperation with other funders

III. Societal

Challenges


Food security, sustainable agriculture and forestry,

water research and bioeconomy





reflective societies Secure Societies - freedom and security of Europe and

its citizens


Health, demographic change & well being 2019-20

Call "Better Health and care, economic growth and sustainable health systems (DG RTD) Priority 1 Personalised medicine

Priority 2 Innovative health and care industry

Priority 3 Infectious diseases and improving global health

Priority 4 Innovative health and care systems - Integration of care

Priority 5 Decoding the role of the environment, including climate change, for health and well-being

Call "Digital transformation in Health and Care" (DG CNECT)

Call "Trusted digital solutions and Cybersecurity in Health and Care"


Research and Innovation Actions (RIA) Innovation Actions (IA)

funding rates

70 % of all eligible costs = direct costs + 25% of direct costs = indirect costs no reimbursement based on real costs

Coordination and Support Actions (CSA)

100 % of all eligible costs = direct costs + 25% of direct costs = indirect costs no reimbursement based on real costs

Reimbursement of costs / funding instruments


Priority 1: Personalised medicine Topic-Titel Instru-

ment Mio € per project / total

Deadline

SC1-BHC-31-2019: Pilot actions to build the foundations of a human cell atlas RIA 3-5/15 16 Apr 19

SC1-BHC-06-2020: Digital diagnostics – developing tools for supporting clinical decisions by integrating in vitro and in vivo diagnostics

SC1-HCO-01-2019: Actions in support of the Internat. Consortium for Personalised Medicine - International aspect: building links with 3rd countries (focus on China) - Standardisation for clinical study design (2019)

CSA CSA

1,5–2 / 2 1,5–2 / 2

02 Apr 19

SC1-HCO-01-2020: Actions in support of the International Consortium for Personalised Medicine: International aspect: building links with 3rd countries (focus on the African Union)

CSA 1,5–2 / 2

SC1-HCO-03-2020: Improving EU-13 participation in EU-supported health research programmes

CSA 1,5-2 / 2


Priority 2: Innovative Health and Care Medicine Topic-Titel Instru-

ment Mio € per project / total

Deadline

SC1-BHC-07-2019: Regenerative medicine: from new insights to new applications RIA 6-8 / 50 16 Apr 19

SC1-BHC-08-2020: New therapies for Non-Communicable Diseases RIA 4-6

SC1-BHC-10-2019: Innovation Procurement: Next generation sequencing (NGS) for routine diagnosis

PCP 9-11 / 30 16 Apr 19

SC1-BHC-11-2020: New, animal-free regulatory test methods for human safety testing at the horizon of 2030


Priority 3: Infectious diseases & improving global health

Topic-Titel Instrument Mio € per project / total

Deadline

SC1-BHC-17-2020: Global Alliance for Chronic Diseases 2 RIA

SC1-BHC-32-2019: Towards a next generation influenza vaccine to protect citizens worldwide – an EU-India collaboration RIA 6-10/15

SC1-BHC-20-2020: Usint pre-commercial procurements of procurements in health care systems to reduce the risk of hospital-acquired infections and/ or improved integrated care PCP/PPI 9-11

SC1-HCO-15-2019: Support for the functioning of the Global Research Collaboration for Infectious Disease Preparedness (GloPID-R)

CSA 1


Priority 4: Innovative health and care systems - Integration of care


Deadline

SC1-BHC-24-2020: Healthcare interventions for the management of the elderly multimorbid patient RIA


Deadline

SC1-BHC-28-2019: The Human Exposome Project: a toolbox for assessing and addressing the impact of environment on health

RIA 8-12 / 50 16 Apr 19

SC1-BHC-29-2020: Environment, climate change and socioeconomic factors- novel mitigating measures for improving population health

SC1- RIA 4 -2020: Micro- and nanoplastics in our environment: Understanding exposures and impacts on human health

Priority 5: Decoding the role of the environment, including climate change, for health and well-being


Call "Digital transformation in Health and Care”

Topic-Titel Instru-ment

Mio € per project / total

Deadline

SC1-DTH-01-2019: Big data and Artificial Intelligence for monitoring health status and quality of life after the cancer treatment RIA 3-5 / 35 24 Apr 19

SC1-DTH-02-2020: Personalised early risk prediction, prevention and intervention RIA

SC1-DTH-04-2020: International cooperation in in digital solutions and robotics for independent living RIA

SC1-DTH-05-2019: Large scale implementation of digital innovation for health & care in an ageing society PPI 2-5 / 10 24 Apr 19

SC1-DTH-06-2020: Accelerating the uptake of in-silico methods for testing medicines RIA 6-8

SC1-DTH-09-2019: Scaling up the univocal Identification of Medicinal Products IA 5-8 / 19 24 Apr 19

SC1-DTH-10-2019-2020: Digital health and care services PCP 5-6 / 22 14 Nov 18

SC1-DTH-11-2019: Large Scale pilots of personalised & outcome based integrated care IA 4-6 / 20 24 Apr 19


Call "Digital transformation in Health and Care”



Deadline

SC1-HCC-02-2019: Support for the large scale uptake of open service platforms in the Active & Healthy Ageing domain

CSA 1,5 / 1,5 24 Apr 19

SC1-HCC-06-2020: Support to eHealth Innovation ecosystems in Europe CSA

SC1-HCC-07-2020: Support for European eHealth Interoperability roadmap for deployment CSA

SC1-HCC-08-2020: Scaling up innovation for active and healthy ageing CSA

SC1-HCC-09-2020: Supporting deployment of eHealth in developing countries for better health outcomes

CSA


Call "Trusted digital solutions & Cybersecurity in Health & Care"



Deadline

DT-TDS-01-2019: Smart and healthy living at home IA 15- 20 /60 14 Nov 18

DT-ICT-12-2020: The smart hospital of the future

DT-TDS-04-2020: Demonstrating the potential and benefits of a European Digital Health Infrastructure for Personalised Medicine

EIC Horizon Prize

Affordable high-tech humanitarian aid Prize 1 15 Jan 20

Early Warning for Epidemics Prize 5 2020

Other Actions: Emergencies

Mobilisation of research funds in case of Public Health Emergencies RIA 10 Mio in case of emergency


Public-Public Partnerships - P2Ps Funding through Member States + partly H2020 Joint Programming Initiatives (member states)

JPND-neuro-deg., MYBL-demogr. change, JPAMR-resistence, JP-AHDL-nutrition and health

ERA-Nets (member states and EC) neuro-degenerative diseases, brain, HIV/AIDS, cancer, rare diseases, CVD, systems medicine, AM

Art. 185 actions (member states and EC) EDCTP2 (Infections Africa), AAL2 (assisted living)

Implementation of Societal Challenge 1

Commission

Funding through H2020

Public Private Partnership(s) – PPPs

Funding through H2020 + industry IMI

Innovative Medicines Initiative (IMI2)


Important European Initiatives Public Private Partnerships (Kommission + Industrie), JTI nach Art. 187

IMI2 www.imi.europa.eu/ pharma, imaging, diagnostics, HTA, etc.

Public Public Partnerships (Kommission + MS) nach Art. 185

EDCTP www.edctp.org/ clinical trials in Sub-Sahara Africa, PRD, NID

Active Assisted Living 2 www.aal-europe.eu/ assistance systems, ehealth, IKT

Public Public Partnerships (MS + z.T. Kommission) Joint Programming und ERA-Nets

JPND www.neurodegenerationresearch.eu Neuro-degenerative diseases

JPI-AMR www.jpiamr.eu/ antimicrobial resistence

JPI-HDHL www.healthydietforhealthylife.eu nutrition & health

JPI-MYBL www.jp-demographic.eu demographic change

ERA-Net Neuron www.neuron-eranet.eu/ neurological diseases

ERA-Net E-Rare www.erare.eu/ rare diseases

ERA-Net TRANSCAN www.transcanfp7.eu/transcan Translational cancer research

ERA-Net ERACoSysMed www.eracosysmed.eu Systems medicine

e ERA-Net EuroNanoMed http://www.euronanomed.net/ Nanomedicin e(KET NMBP)

ERA-Net CVD http://www.era-cvd.eu/ Cardiovascular diseases

ERA PerMed http://www.erapermed.eu/ Personalised medicine

Knowledge and Innovation Community (KIC) des European Institute of Innovation and Technology (EIT)

EIT health www.eithealth.eu Demograph. Change, health economics

European Innovation Partnerships - EIPs

AHA, Active and healthy ageing https://webgate.ec.europa.eu/eipaha/ Demographic change

http://www.imi.europa.eu/

http://www.edctp.org/

http://www.aal-europe.eu/

http://www.neurodegenerationresearch.eu/

http://www.jpiamr.eu/

https://www.healthydietforhealthylife.eu/

http://www.jp-demographic.eu/

http://www.neuron-eranet.eu/

http://www.erare.eu/

http://www.transcanfp7.eu/transcan

http://www.eracosysmed.eu/

http://www.euronanomed.net/

http://www.era-cvd.eu/

http://www.erapermed.eu/

http://www.eithealth.eu/

http://www.webgate.ec.europa.eu/eipaha/


IMI2

Public Private Partnership 3.45 billion EUR

Zulassungs-behörden

Patient organisa-

tions

SME

Acade-mia

EFPIA companies

(+other industries)

„Public“ Consortia

EFPIA/industry Consortia

non.-EFPIA companies

1.75 bn. (in kind)

1.75 bn. H2020

• increased budget • broadened thematic scope • participation of additional industries (e.g. medical technology, ICT vaccines, imaging)

Mid-Caps

Priorities of IMI2: • a 30% better success rate in clinical trials of priority

medicines identified by the WHO; • clinical proof of concept in immunological, respiratory,

neurological & -degenerative diseases in just 5 years; • new approved diagnostic markers for 4 of these diseases

and at least 2 new medicines which could either be new antibiotics or new therapies for Alzheimer’s disease.


Rules of Participation

In general: at least 3 independent legal entities from 3 different EU Member States (MS) or associated states (AS) Exception:

• ERC • Marie Skłodowska-Curie Actions • SME instrument • CSA • Explicitely mentioned in work programme

1

3


States and institutions eligible for funding

Treated equally

28 EU member states (MS)

Associated / candidate states (AS): AL, AM, BA, CH, FO, GE, IL, IS, MD, ME, MK, NO, RS, TN, TR, UA

Eligible for funding

Third countries with low or medium incomes

(listed in Annex A of WP)

High-income countries incl. BRIC + Mexico Only in exceptional cases* or when mentioned in WP

Third countries

* Exception in Health: institutions from the US are eligible for funding in many topics

Joint Research Centre (JRC)


Eligible organisations / legal entities

universities

industry (incl. SME)

research institutes

management and tt-organisations

others, e.g. agencies, associations, patient organisations, etc.

European economic interest groups


Evaluation process

Funding decisions based on peer review of research proposals

Independent experts: • Are the core of the evaluation system • Invited on call-by-call basis • Balanced selection of experts (background geography, gender, rotation) • Sign confidentiality agreement & absence of conflict of interest declaration • The identity of the evaluators remains confidential • 3 Evaluation criteria: excellence, impact, implemention

Commission staff:

• Manage evaluation, ensure fairness & protect confidentiality of proposals • Not involved in evaluation per se

38


Further Information

• Official Horizon 2020 documents incl. work programmes: http://ec.europa.eu/research/participants/portal/desktop/en/funding/reference_docs.html

• National Symposium of the NKS-L: 21st of November in Cologne

• NKS-L workshops, seminars for proposal writing

• All other relevant information published in our newsletter. registration via: http://www.nks-lebenswissenschaften.de/de/1676.php

• NKS-L homepage: http://www.nks-lebenswissenschaften.de

http://ec.europa.eu/research/participants/portal/desktop/en/funding/reference_docs.html



http://www.nks-lebenswissenschaften.de/de/1676.php

http://www.nks-lebenswissenschaften.de/


How to obtain funding? What to do in a nutshell:

• Apply to the right call for proposals • Find the right documents • Understand evaluation process • Follow the instructions and guidance papers • Respect formal demands (page limits, templates etc.) • Draft your concept (project idea), including objectives • Build your core project group • Create work plan, including time table and budget plan • Emphasize the European, innovative and societal dimensions • Write the proposal for the evaluators


http://ec.europa.eu/research/participants/portal/desktop/en/home.html

Where to find calls and documents

https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/home

http://ec.europa.eu/research/participants/portal/desktop/en/home.html

https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/home


Dr. Uta Baddack-Werncke

National Contact Point Health

DLR project management agency (DLR – Projektträger)

Heinrich-Konen-Str. 1

53227 Bonn

Tel. 0228 3821 1692 Fax 0228 3821 1699

E-Mail [email protected]

[email protected] www.nks-lebenswissenschaften.de

We are there to support you!

eu funding opportunities for health research in …...eu funding opportunities for health research...

Documents